Triple negative breast cancer

69 clinical trials

Quick filters

Clinical trials for Triple negative breast cancer

69 trials across Europe

See all trials →

Quick filters

69 Clinical trials

Triple negative breast cancer+4

Recruiting

Registered drugNo placebo

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sacituzumab Govitecan
Sponsor:Unicancer

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Durvalumab
Sponsor:Queen Mary University Of London

Contact Research Centre

Breast cancer+1

Recruiting

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

See all trials →

Triple negative breast cancer

Clinical trials for Triple negative breast cancer

Triple negative breast cancer+4

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Triple negative breast cancer

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Triple negative breast cancer

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Triple negative breast cancer

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Triple negative breast cancer

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Breast cancer+1

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.